What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
Open Access
- 1 January 2015
- journal article
- review article
- Published by BMJ in Open Heart
- Vol. 2 (1), e000283
- https://doi.org/10.1136/openhrt-2015-000283
Abstract
Each year in the USA there are over 1 million hospital admissions directly related to heart failure (HF). With similar rates across Europe, this places a huge economic burden on healthcare systems globally. Hospitalisation for HF is associated with poor clinical outcomes with 25% of patients being readmitted with signs and symptoms of HF within 1 month of discharge and 10–20% dying in the 6 months after discharge. Although hospital admission could be a sign of disease progression, it is also possible that some of the treatments given acutely for example, inotropic therapy, may result in neurohormonal, haemodynamic and other effects accelerating end-organ damage and contributing to these poor outcomes after discharge. In contrast to the treatment of chronic heart failure (CHF), clinical trials conducted over the past decade in patients with acute HF (AHF) have failed to show significant reductions in morbidity or mortality despite some agents causing beneficial changes in symptoms. As such, the current treatment of patients hospitalised with HF is mainly based on consensus rather than clinical evidence and has changed little over time. We review RELAX-AHF in the context of the other key, large-scale AHF trials conducted over the past 15 years and compare and contrast study design and outcomes in an attempt to determine which factors might be associated with a successful trial in the future.Keywords
This publication has 28 references indexed in Scilit:
- Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHFEuropean Heart Journal, 2013
- Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development ProgramJournal of the American College of Cardiology, 2012
- Ultrafiltration in Decompensated Heart Failure with Cardiorenal SyndromeThe New England Journal of Medicine, 2012
- Design of the RELAXin in Acute Heart Failure StudyAmerican Heart Journal, 2012
- Neurohormonal Activation in Acute Heart Failure: Results from VERITASCardiology, 2011
- Effect of Nesiritide in Patients with Acute Decompensated Heart FailureThe New England Journal of Medicine, 2011
- Diuretic Strategies in Patients with Acute Decompensated Heart FailureThe New England Journal of Medicine, 2011
- The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea studyEuropean Heart Journal, 2009
- Early worsening heart failure in patients admitted with acute heart failure – a new outcome measure associated with long‐term prognosis?Fundamental & Clinical Pharmacology, 2009
- Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF)Journal of Cardiac Failure, 2008